

# BCBSMT HEDIS® 2013 COMPARISON REPORT - PPO

## EFFECTIVENESS OF CARE MEASURES

	BCBSMT 2011			BCBSMT 2012			% change	BCBSMT 2013			% change	2012 QC National	2013 QC National
	Num	Denom		Num	Denom			Num	Denom				
<b>Childhood Immunization****</b>	<b>n=822</b>			<b>n=849</b>				<b>n=473</b>					
DTaP	393	822	47.81%	442	849	52.06%	8.89%	399	473	84.36%	na	76.80%	80.00%
Hib	499	822	60.71%	591	849	69.61%	14.67%	426	473	90.06%	na	86.10%	88.30%
IPV	464	822	56.45%	522	849	61.48%	8.92%	426	473	90.06%	na	83.40%	86.30%
PCV	390	822	47.45%	470	849	55.36%	16.68%	390	473	82.45%	na	77.70%	78.90%
HepB	396	822	48.18%	400	849	47.11%	-2.20%	411	473	86.89%	na	74.70%	77.30%
MMR	631	822	76.76%	685	849	80.68%	5.11%	421	473	89.01%	na	86.90%	88.30%
VZV	587	822	71.41%	656	849	77.27%	8.20%	398	473	84.14%	na	86.90%	88.00%
HepA ^	174	822	21.17%	213	849	25.09%	18.52%	339	473	71.67%	na	32.30%	61.10%
Rotavirus	305	822	37.10%	396	849	46.64%	25.71%	331	473	69.98%	na	67.20%	69.80%
Influenza	294	822	35.77%	306	849	36.04%	0.77%	268	473	56.66%	na	57.30%	59.80%
Combo-1	na	822	na	na	849	na	na	398	473	84.14%	na	na	na
Combo-2	287	822	34.91%	304	849	35.81%	2.55%	358	473	75.69%	na	64.80%	68.10%
Combo-3	274	822	33.33%	293	849	34.51%	3.53%	339	473	71.67%	na	63.10%	65.80%
Combo-4 ^	93	822	11.31%	95	849	11.19%	-1.10%	282	473	59.62%	na	na	na
Combo-5	194	822	23.60%	222	849	26.15%	10.79%	273	473	57.72%	na	na	na
Combo-6	163	822	19.83%	144	849	16.96%	-14.47%	229	473	48.41%	na	na	na
Combo-7 ^	78	822	9.49%	82	849	9.66%	1.78%	252	473	53.28%	na	na	na
Combo-8 ^	57	822	6.93%	56	849	6.60%	-4.88%	202	473	42.71%	na	na	na
Combo-9	126	822	15.33%	123	849	14.49%	-5.49%	201	473	42.49%	na	na	na
Combo-10 ^	52	822	6.33%	53	849	6.24%	-1.32%	188	473	39.75%	na	17.00%	29.50%
<b>Adolescent Immunizations****</b>	<b>n=953</b>			<b>n=1111</b>				<b>n=471</b>					
Meningococcal (MCV)	263	953	27.60%	373	1111	33.57%	21.66%	202	471	42.89%	na	51.40%	57.10%
Tdap/Td	504	953	52.89%	668	1111	60.13%	13.69%	390	471	82.80%	na	65.40%	69.90%
Combo-1	238	953	24.97%	356	1111	32.04%	28.31%	201	471	42.68%	na	48.20%	54.30%
<b>HPV Vaccine for Female Adolescents****</b>	<b>na</b>			<b>n=571</b>				<b>n=472</b>					
	na	na	na	50	571	8.76%	na	43	472	9.11%	4.04%	na	na
<b>Appropriate Tx for Children w/ URI</b>	<b>n=1436</b>			<b>n=1900</b>				<b>n=1484</b>					
	1196	1436	83.29%	1520	1900	80.00%	-3.95%	1184	1484	79.78%	-0.27%	82.00%	82.30%
<b>Appropriate Testing for Children w/ Pharyngitis</b>	<b>n=1101</b>			<b>n=1523</b>				<b>n=1102</b>					
	732	1101	66.49%	1095	1523	71.90%	8.14%	772	1102	70.05%	-2.56%	79.30%	78.90%
<b>Avoidance of Antibiotic Tx for Adults w/ Acute Bronchitis</b>	<b>n=1164</b>			<b>n=1356</b>				<b>n=1289</b>					
	226	1164	19.42%	296	1356	21.83%	12.43%	270	1289	20.95%	-4.04%	21.50%	21.40%
<b>Colorectal Cancer Screening</b>	<b>n=18,017</b>			<b>n=22,436</b>				<b>n=22096</b>					
	6560	18,017	36.41%	8437	22,436	37.60%	3.28%	9186	22096	41.57%	10.55%	54.60%	55.80%

**EFFECTIVENESS OF CARE MEASURES**

**BCBSMT 2011**

**BCBSMT 2012**

**BCBSMT 2013**

**2012 QC National**

**2013 QC National**

	Num	Denom		Num	Denom	% change	Num	Denom	% change				
<b>Breast Cancer Screening</b>	<b>n=14,162</b>		<b>n=17,487</b>				<b>n=16948</b>						
	9235	14,162	65.21%	11,514	17,487	65.84%	0.97%	11136	16948	65.71%	-0.21%	66.70%	66.50%
<b>Cervical Cancer Screening</b>	<b>n=16,352</b>		<b>n=21,765</b>				<b>n=16820</b>						
	11,682	16,382	71.31%	15,535	21,765	71.38%	0.09%	11964	16820	71.13%	-0.35%	74.40%	73.60%
<b>Persistence of Beta Blocker Treatment after Heart Attack</b>	<b>n=32</b>		<b>n=49</b>				<b>n=46</b>						
	25	32	78.13%	41	49	83.67%	7.10%	38	46	82.61%	-1.27%	77.00%	79.50%
<b>Cholesterol Management for Patients**** w/ Cardiovascular Conditions</b>	<b>n=490</b>		<b>n=587</b>				<b>n=461</b>						
LDL-screening	364	490	74.29%	436	587	74.28%	-0.01%	373	461	80.91%	8.93%	83.50%	83.70%
LDL-C level < 130 mg/dL	na	490	na	na	587	na	na	276	461	59.87%	na	na	na
LDL-C level < 100 mg/dL	na	490	na	na	587	na	na	223	461	48.37%	na	50.10%	49.70%
<b>Comprehensive Diabetes Care****</b>	<b>n=2224</b>		<b>n=2805</b>				<b>n=617</b>						
HbA1c Tested	1868	2224	83.99%	2370	2805	84.49%	0.59%	548	617	88.82%	5.12%	87.00%	87.20%
Poor HbA1c Control >9.0% *	na	2224	na	na	2805	na	na	220	617	35.66%	na	33.50%	35.20%
HbA1c < 8.0%	na	2224	na	na	2805	na	na	337	617	54.62%	na	55.20%	54.50%
HbA1c < 7.0% **	na	1750	na	na	2188	na	na	135	433	31.18%	na	36.40%	36.00%
Eye Exam	866	2224	38.94%	1011	2805	36.04%	-7.44%	336	617	54.46%	51.09%	48.40%	48.80%
LDL Screening	1571	2224	70.64%	1921	2805	68.48%	-3.05%	465	617	75.36%	10.05%	81.20%	81.70%
LDL Level < 130 mg/dL	na	2224	na	na	2805	na	na	317	617	51.38%	na	na	na
LDL Level < 100 mg/dL	na	2224	na	na	2805	na	na	222	617	35.98%	na	41.80%	41.70%
Nephropathy Monitored	1636	2224	73.56%	2036	2805	72.58%	-1.33%	479	617	77.63%	6.96%	77.90%	78.60%
Blood Pressure < 140/80 mmHg	na	2224	na	na	2805	na	na	262	617	42.46%	na	38.10%	37.50%
Blood Pressure < 140/90 mmHg	na	2224	na	na	2805	na	na	377	617	61.10%	na	59.40%	58.30%
<b>Follow-up for Mental Illness</b>	<b>n=152</b>		<b>n=167</b>				<b>n=294</b>						
7 days	85	152	55.92%	80	167	47.90%	-14.34%	146	294	49.66%	3.66%	54.00%	53.00%
30 days	116	152	76.32%	127	167	76.05%	-0.35%	207	294	70.41%	-7.42%	72.70%	72.20%
<b>Antidepressant Medication Management</b>	<b>n=643</b>		<b>n=620</b>				<b>n=746</b>						
Effective Acute Phase Tx	424	643	65.94%	418	620	67.42%	2.24%	532	746	71.31%	5.78%	64.90%	68.90%
Effective Continuation Phase TX	313	643	48.68%	316	620	50.97%	4.70%	402	746	53.89%	5.73%	48.80%	53.40%
<b>Follow-Up for Children Prescribed ADHD Medication</b>	<b>n=145</b>		<b>n=136</b>				<b>n=142</b>						
Initiation Phase Visit	55	145	37.93%	56	136	41.18%	8.56%	47	142	33.10%	-19.62%	39.40%	38.10%
<b>Use of Appropriate Medications for People with Asthma***</b>	<b>n=508</b>		<b>n=812</b>				<b>n=739</b>						
Ages 5-11	80	84	95.24%	78	87	89.66%	-5.86%	65	67	97.01%	8.21%	96.60%	95.70%
Ages 12-18	na	na	na	75	82	na	na	74	79	93.67%	na	93.10%	92.20%
Ages 19-50	na	na	na	316	364	na	na	289	345	83.77%	na	88.30%	87.40%

**EFFECTIVENESS OF CARE MEASURES**

**BCBSMT 2011**

**BCBSMT 2012**

**BCBSMT 2013**

**2012 QC National**

**2013 QC National**

	Num	Denom		Num	Denom		% change	Num	Denom		% change		
Ages 51-64	na	na	na	256	279	na	na	224	248	90.32%	na	93.00%	92.20%
Combined ***	460	508	90.55%	725	812	89.29%	-1.40%	652	739	88.23%	-1.19%	91.60%	90.70%
<b>Use of Spirometry in the Assessment &amp; Diagnoses of COPD</b>			<b>n=228</b>			<b>n=195</b>				<b>n=182</b>			
	72	228	31.58%	60	195	30.77%	-2.56%	68	182	37.36%	21.43%	40.50%	41.50%
<b>Pharmacotherapy Management of COPD Exacerbation</b>			<b>n=25</b>			<b>n=45</b>				<b>n=40</b>			
Bronchodilator	20	25	80.00%	30	45	66.67%	-16.67%	30	40	75.00%	12.50%	76.80%	77.70%
Systemic Corticosteroid	21	25	84.00%	26	45	57.78%	-31.22%	34	40	85.00%	47.12%	69.50%	70.80%
<b>Chlamydia Screening</b>			<b>n=3002</b>			<b>n=3843</b>				<b>n=5241</b>			
Ages 16-20	423	1296	32.64%	525	1681	31.23%	-4.31%	792	2233	35.47%	13.57%	39.60%	38.90%
Ages 21-24	644	1706	37.75%	814	2162	37.65%	-0.26%	1157	3008	38.46%	2.16%	44.90%	45.50%
Combined	1067	3002	35.54%	1339	3843	34.84%	-1.97%	1949	5241	37.19%	6.73%	42.40%	42.30%
<b>Use of Imaging Studies for Low Back Pain</b>			<b>1644</b>			<b>n=1797</b>				<b>n=1814</b>			
	1335	1644	81.20%	1465	1797	81.52%	0.39%	1488	1814	82.03%	0.62%	73.70%	74.20%
<b>DMARD Therapy in Rheumatoid Arthritis</b>			<b>n=281</b>			<b>n=311</b>				<b>n=357</b>			
	256	281	91.10%	279	311	88.89%	-2.43%	314	357	87.96%	-1.05%	86.70%	87.20%
<b>Annual Monitoring for Patients on Persistent Medications</b>			<b>n=8395</b>			<b>n=9539</b>				<b>n=9623</b>			
ACE/ARB	3305	4544	72.73%	3833	5254	72.95%	0.30%	3782	5344	70.77%	-2.99%	78.80%	79.20%
Anticonvulsant	122	186	65.59%	124	230	53.91%	-17.80%	108	200	54.00%	0.16%	56.90%	56.30%
Digoxin	99	122	81.15%	103	122	84.43%	4.04%	78	97	80.41%	-4.75%	79.20%	80.60%
Diuretic	2575	3543	72.68%	2820	3933	71.70%	-1.35%	2833	3982	71.15%	-0.78%	78.40%	78.70%
Combined	6101	8395	72.67%	6880	9539	72.12%	-0.76%	6801	9623	70.67%	-2.01%	78.20%	78.50%

\* Note: For this numerator, a lower rate indicates better performance.

\*\* Note: The HbA1c < 7.0% denominator excludes members w/ certain conditions. Please see measure description for a list of conditions.

\*\*\* Note: The combined age range for this measure changed from 5-50 years in 2011 to 5-64 years in 2012 & 2013.

\*\*\*\*Note: mMedical record review was completed on these measures for HEDIS 2013, not HEDIS 2011 or 2012.

^The NCQA qualifying dosing requirements for the Hepatitis A immunizations series changed from 2 doses in 2011 & 2012 to 1 dose in 2013.

BCBSMT 2011 rates based on 2010 data.

BCBSMT 2012 rates based on 2011 data.

BCBSMT 2013 rates based on 2012 data.

The 2013QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2013 Report* and reflect 2012 data.

The 2012 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2012 Report* and reflect 2011 data.